Affymetrix and Beckman Coulter Join Forces to Provide Automated Target Preparation Solutions
News Sep 02, 2009
Affymetrix, Inc. and Beckman Coulter, Inc. have announced that they have entered into an agreement to offer researchers co-developed products in microarrays and automated liquid handlers. The collaboration will provide scientists with optimized, robust solutions for genomic research, fortified by end-to-end support.
The partnership will yield an expanding list of Affymetrix-validated automated target preparation methods, developed on an Affymetrix-specific configuration of Beckman Coulter’s Biomek FXp Dual Arm Multichannel–Span 8 Liquid Handler. This platform will provide researchers with standardized systems that include all components necessary to run Affymetrix genotyping and gene expression assays.
Major benefits of the solution will include the flexibility to process samples using Affymetrix GeneChip® Arrays or Array Plates with a single method, user-friendly interfaces, implementation of new methods, a validated platform and delivery of high-quality results.
Automated target preparation solutions from Affymetrix and Beckman Coulter are for research use only and are not for use in diagnostic procedures.
The Biomek FXp Dual Arm Multichannel–Span 8 Liquid Handler is for laboratory use only and not for use in diagnostic procedures.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.
Researchers published today a detailed description of the complete genome of bread wheat, the world's most widely-cultivated crop. This work will pave the way for the production of wheat varieties better adapted to climate challenges, with higher yields, enhanced nutritional quality and improved sustainability.